Key Takeaways:
Adaptive Biotechnologies is separating its profitable MRD diagnostics business from its Immune Medicine unit, betting each will be worth more apart.
Adaptive Biotechnologies Corp. plans to split its Minimal Residual Disease diagnostics business from its Immune Medicine discovery unit, a separation that could unlock value in a diagnostics franchise that grew revenue to $212 million last year.
"The progress achieved by both businesses has reinforced that decision," Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies, said in a statement. "We believe this separation is the best way to unlock the full potential of both businesses."
The MRD business, anchored by the clonoSEQ platform, generated $15 million in adjusted EBITDA in 2025 on $212 million in revenue, up from $103 million in 2023. It now covers more than 300 million insured lives and supports over 180 active biopharma trials. The Immune Medicine unit, by contrast, remains pre-revenue but has built a database of more than 6 million functional T-cell receptor-antigen pairs and clinical data on over 10,000 patients.
Adaptive expects to identify its preferred separation path by year-end 2026. The company also announced a $250 million convertible note offering due 2031, with proceeds earmarked for share repurchases, repayment of its OrbiMed purchase agreement, and opportunistic investments in the MRD business. Adaptive shares have gained 69% over the past year, giving it a market capitalization of about $2.8 billion.
MRD's Path to Profitability Sets the Stage
The diagnostics business has transformed from a money-losing operation into a cash-generating franchise in just two years. Revenue more than doubled between 2023 and 2025, and the segment reached profitability on an adjusted basis last year. clonoSEQ, which detects residual cancer cells in blood cancer patients after treatment, has become embedded in routine clinical practice with more than 175 electronic medical record-integrated accounts. The platform competes in a growing MRD testing market that analysts at MarketsandMarkets have estimated could reach $4.5 billion by 2028, with liquid biopsy approaches gaining share over traditional tissue biopsies.
Immune Medicine's Data Bet Faces a Funding Test
The Immune Medicine unit represents a longer-term bet on using the adaptive immune system to discover autoimmune disease targets. Its platform combines the world's largest clinically linked immune receptor dataset with artificial intelligence-driven discovery tools to identify pathogenic T-cell receptors and the disease-causing antigens they bind. The technology has attracted biopharma partnerships, but the unit has not generated meaningful revenue and requires continued investment. Adaptive is evaluating strategic alternatives including a sale, partnership, or licensing transaction, with a decision expected by the end of 2026. The convertible note offering provides near-term liquidity, but the separation timeline means Immune Medicine will need to demonstrate its commercial viability to external investors.
The restructuring comes as biotech companies increasingly use corporate separations to sharpen strategic focus. Adaptive's move mirrors a broader trend in which life sciences firms are shedding non-core assets to concentrate resources on their strongest businesses. For Adaptive, the bet is that a pure-play MRD diagnostics company will command a higher valuation multiple than a combined entity that also carries the cost of an early-stage drug discovery platform. The company reported $295 million in trailing 12-month revenue and a net loss of $49.7 million, underscoring the drag from Immune Medicine's development costs.
This article is for informational purposes only and does not constitute investment advice.
